Abstract
Topical treatment of ocular surface diseases associated with dryness is still based on the principles of lubrication and anti-inflammation with corticosteroids and cyclosporine, as in cases of Sjogren's Syndrome, whose effectiveness is limited. New pharmacotechnical technologies can overcome the problems of bioavailability and therapeutic efficacy. Nanoemulsion drug delivery systems can b…